Abstract
Gene therapy for treatment of glioma often involves delivery of herpes simplex virus-1 thymidine kinase gene. A new study shows that this approach can induce chronic inflammation, and raises important questions about current adenoviral-based clinical trials (pages 1256–1263).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Freeman, S.M., Ramesh, R. & Marrogi, A.J. Immune system in suicide-gene therapy. Lancet 349, 2–3 ( 1997).
Dewey, R.A. et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials. Nature Med. 5, 1256–1263 (1999).
Kruse, C.A. et al. A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: A comparison to 9L gliosarcoma. J. Neuro-Oncol. 22, 191–200 ( 1994).
Yang, Y. et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl. Acad. Sci. USA 91, 4407–4411 (1994).
Worgall, S. et al. Selective expansion of alveolar macrophages in vivo by adenovirus-mediated transfer of the murine granulocyte-macrophage colony-stimulating factor cDNA. Blood 93, 655– 666 (1999).
McRae, B.L., Vanderlugt, C.L., Dal Canto, M.C., & Miller, S.D. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 182, 75–85 (1995).
Miller, S.D. et al. Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases. Immunol. Rev. 144, 225–244 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kielian, T., Hickey, W. Inflammatory thoughts about glioma gene therapy. Nat Med 5, 1237–1238 (1999). https://doi.org/10.1038/15188
Issue Date:
DOI: https://doi.org/10.1038/15188